Login to Your Account

Other News To Note

Friday, March 11, 2011
MediGene AG, of Martinsreid, Germany, signed an exclusive license and supply agreement with Will-Pharma for commercialization and marketing of Veregen ointment for genital warts in Belgium, the Netherlands, and Luxembourg. It has existing agreements covering the U.S., other parts of Europe, Latin America and Asia. It will continue to pursue a global licensing strategy for the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription